FAT1 and melanoma: In the pooled melanoma cohort, univariate survival analysis revealed that patients with FAT1 mutations had a significantly improved ICI prognosis than those wild-type patients (median survival time: 41.9 vs. 25.6 months, Log-rank test P = 0.013; Fig. 2a).